BridgeBio Pharma BBIO
NASDAQ BBIO
$79.54 +0.87 (+1.11%)
At close: Nov 11, 2026 · 4:00 PM EST

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2018 - 2024)

Updated

BridgeBio Pharma (BBIO) posted Long-Term Debt Repayments of $473.42 million for Q1 2024.

Analysis

BridgeBio Pharma (BBIO) Long-Term Debt Repayments (2018 - 2024) Analysis & Trends

For FY2022, BridgeBio Pharma's Long-Term Debt Repayments came in at $20.49 million, down 83.5% from FY2021.

  • Annual Long-Term Debt Repayments shows a four-year compound annual growth rate of 107.9% (FY2018 to FY2022).
  • In prior years, BridgeBio Pharma's Long-Term Debt Repayments was $124.12 million in FY2021 and $1.1 million in FY2018.
  • The Q1 2024 figure stands as the lowest quarterly Long-Term Debt Repayments since Q4 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn -
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 1.00 Mn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn -
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn -
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -4.91 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 3.05 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 19.00 Mn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn -
10 BridgeBio Pharma 15.42 Bn 11.64 Bn 332.72 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 473.42 Mn
Dec 31, 2021 106.01 Mn
Dec 31, 2018 441,000.00
Sep 30, 2018 639,000.00
API Access

BridgeBio Pharma Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=BBIO&period=max&api_key=YOUR_API_KEY